Business Wire

SUZANO-VENTURES

24.4.2024 09:02:29 CEST | Business Wire | Press release

Share
Suzano Ventures invests up to US$5 million into Bioform Technologies to further develop bio-based plastic alternatives

Suzano Ventures, the corporate venture capital arm of Suzano, the world’s largest market pulp producer, has made a strategic investment into the Canadian materials science startup, Bioform Technologies. The investment provides up to US$5 million towards the company’s seed round, enabling it to accelerate the development of its novel bio-based plastic alternatives. The products can be manufactured through modified industrial processes already used in the pulp and paper sector.

Bioform’s proprietary technology rapidly produces wood pulp-reinforced hydrogels to create high-performance plastic alternatives, which can be made using Suzano’s wood pulp fibre as a key input. Bioform’s materials have the potential to be home compostable or recycled through existing paper recycling processes and do not require fossil-based inputs. The technology is highly versatile and has a number of applications where it could replace conventional single-use plastics, including paper recyclable thermoformable films for packaging applications and compostable heat-sealable films for pouches, agriculture, and garbage bags.

With the potential to offer an 80 percent lower carbon footprint than conventional single-use plastics, Bioform’s technology has similar or enhanced product performance to conventional plastics in areas such as tensile strength and permeability for oxygen or water vapor.

Chris Clark, Chief Executive Officer of Bioform Technologies, said:

“Our goal is to produce sustainable alternatives to single-use plastics at the speed of paper and at the cost of plastic. We are harnessing the speed and efficiency of pulp and paper manufacturing to make swift and impactful steps into the marketplace. The technical validation and strategic investment from Suzano Ventures gives us a link to the world’s largest market pulp producer. We can also access Suzano’s world-leading expertise to help us rapidly accelerate the production efficiencies and cost reductions needed to make a significant reduction in the reliance on single-use plastics.”

Paula Puzzi, Senior Manager at Suzano Ventures, said:

“We’ve looked closely at Bioform’s technology and we see great promise in their technology and ability to disrupt the industry. Around the world, there are a number of innovations being developed that each offer more sustainable alternatives to the mountains of single-use plastic that we throw away each year, polluting our cities and soils, rivers, and seas. The great challenge is scaling production and getting to cost competitiveness versus cheap single-use plastic. By using renewable material and harnessing established industrial processes and machinery from the pulp and paper sector, we believe that Bioform has the opportunity to disrupt established supply chains and rapidly replace the need for fossil-based materials.”

Bioform has previously raised US$2.4 million from direct investments and US$1.2 million from non-dilutive sources to streamline its technology and validate performance and processes in its labs. This funding from Suzano Ventures will enable the company to realize a demonstration facility to pilot its manufacturing process and expand its team and capabilities.

Headquartered in São Paulo, Brazil, Suzano is the world’s largest market pulp producer and one of Latin America’s largest paper manufacturers. Producing its pulp entirely from farmed eucalyptus, the company’s products reach over 2 billion people around the world in over 100 countries. Suzano has had a presence in Canada since 2015, with a large research and development center for pulp, paper, and biomaterials technologies located in Vancouver.

About Suzano Ventures

Suzano Ventures is the venture capital arm of Suzano, the world’s largest market pulp producer - the key raw material for paper and packaging products that are part of the lives of more than 2 billion people around the world in over 100 countries. We invest globally in businesses that are pioneering innovative approaches to harness the power of trees, to help build the future of the bioeconomy.

We are committing an initial US$70 million to support the development and growth of companies across four investment areas: novel applications for eucalyptus biomaterials, sustainable packaging, forestry technology, and carbon removal. We help startups to grow, which in turn have the potential to develop and help shape the future of Suzano’s business.

Our strategic investments deliver shared value. By placing science at the heart of business, we help early-stage startups to grow, which, in turn, have the potential to develop and help shape the future of Suzano's business.

We provide our portfolio companies with capital, technical expertise, and market insights, alongside access to our global operations, supply chain and customer base. This includes the ability to engage with our hundreds of scientists, engineers, and technologists, based at Suzano’s research centers and operations across four continents.

www.suzanoventures.com

About Bioform Technologies

Founded in 2021, Bioform has developed a proprietary method to manufacture plastic alternatives based on wood pulp reinforced hydrogels at high speeds by modifying existing pulp and paper making machinery. The manufacturing process has a low carbon footprint and can produce highly versatile materials to replace a wide range of single use plastics. Bioform has developed both compostable and paper-recyclable films that can be heat sealed or thermoformed depending on the application.

Bioform’s core technology was developed at the University of British Columbia by co-founders Jordan MacKenzie, the company’s current CTO, and Mark Martinez, Professor, Bio-Products Institute, University of British Columbia.

For further information please contact Chris Clark at cclark@bioformtech.com

www.bioformtech.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240424575263/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release

New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that

SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release

SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun

Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release

New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e

Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c

Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release

Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye